On September 10, 2020 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, reported that members of management will present virtually at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 14th and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22nd (Press release, Moleculin, SEP 10, 2020, View Source [SID1234564930]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. (PRNewsfoto/Moleculin Biotech, Inc.)

H.C. Wainwright 22nd Annual Global Investment Conference:
Date: Monday, September 14th, 2020
Time: 5:00 PM ET
Link: View Source

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit:
Date: Tuesday, September 22nd, 2020
Time: 10:00 AM ET
Link: View Source

Replays of the presentations will be available on the Company’s website for 90 days following the event. Members of management will hold 1-on-1 virtual investor meetings at the conferences. Investors attending the conferences virtually who are interested in meeting with Company management should contact their H.C Wainwright and Oppenheimer representatives.